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Connective tissue growth factor (CCN2), a member of the CCN family of proteins, is a cysteine-rich matricellular
protein. Connective tissue growth factor is not normally expressed in dermal ﬁbroblasts unless induced. The most
potent inducer of connective tissue growth factor thus far identiﬁed is transforming growth factor b. Connective
tissue growth factor, however, is constitutively overexpressed by ﬁbroblasts present in skin ﬁbrotic lesions,
including scleroderma. The overexpression of connective tissue growth factor present in ﬁbrotic lesions
contributes to the phenotype of scleroderma in that connective tissue growth factor promotes matrix deposition,
and ﬁbroblast adhesion and proliferation. In animal models, whereas either transforming growth factor b or
connective tissue growth factor alone produce only a transient ﬁbrotic response, connective tissue growth factor
and transforming growth factor b act together to promote sustained ﬁbrosis. Thus the constitutive overexpression
of connective tissue growth factor by ﬁbroblasts present in ﬁbrotic lesions would be expected to contribute directly
to chronic, persistent ﬁbrosis. This review discusses recent information regarding insights into connective tissue
growth factor biology and, using scleroderma as a model system, the part connective tissue growth factor might
play in ﬁbrotic disease.
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The extracellular matrix (ECM) is essential in establishing
and maintaining the structural and mechanical integrity of
skin (Nimni, 1974; Kielty and Shuttleworth, 1997). Virtually
every person at some point in their life suffers skin damage,
and tissue repair occurs effectively. If the tissue repair
process is not appropriately terminated, however, excessive
deposition of ECM occurs resulting in the deposition of
excessive scar tissue (Silver and Glasgold, 1995). These
scars are generally limited in their nature; however, although
relatively rare, progressive, pathologic, fatal scarring (fibro-
tic) disorders can occur. One example of such a connective
tissue disease is systemic sclerosis (scleroderma; SSc),
which affects the skin as well as internal organs (Simms and
Korn, 2002; Valentini and Black, 2002). There is no effective
treatment for this disorder, in part because the etiology of
this disease is unknown. Thus, in order to develop effective
anti-scarring therapies it is necessary to understand the
molecular players in the normal wound healing process and
how these proteins normally interact to co-ordinate the
proper repair of the epidermis and dermis, and to under-
stand how this process goes awry, leading to scarring and
fibrosis.
One of the major cytokines involved with tissue repair
and fibrosis in general is transforming growth factor (TGF)-
b. TGF-b promotes deposition of the ECM by inducing
expression of matrix genes (Ignotz and Massague, 1986;
Quaglino et al, 1991) and decreasing the expression of
matrix metalloproteinases while increasing that of tissue
inhibitors of metalloproteinases (Overall et al, 1989, 1991;
Yuan and Varga, 2001). Anti-TGF-b strategies, such as an
anti-TGF-b antibody and an adenovirus overexpressing
Smad7, are effective at blocking fibrosis in animal models
(McCormick et al, 1999; Nakao et al, 1999; Yamamoto et al,
1999; Terada et al, 2002; Lan et al, 2003). In addition, mice
knocked out for TGF-b or Smad 3 show alterations in
wound healing, such as enhanced re-epithelialization and
suppressed matrix deposition; however, these mice also
show an impaired inflammatory response (Letterio and
Roberts, 1996; Ashcroft et al, 1999; Crowe et al, 2000;
Flanders et al, 2002) consistent with the notion that TGF-b
controls a wide range of physiologic functions (McCartney-
Francis et al, 1998). Thus using a global anti-TGF-b strategy
as a prolonged treatment to combat chronic fibrosis might
be expected to have harmful consequences for human
health.
The protein connective tissue growth factor (CTGF) was
initially discovered in 1991 as a secreted protein in the
conditioned media of cultured human umbilical vascular
endothelial cells (Bradham et al, 1991). In adult skin,
however, CTGF is not normally expressed unless induced,
for example during the normal wound repair process
(Igarashi et al, 1993). One of the most exciting early
observations concerning CTGF was that TGF-b induced
CTGF expression in dermal fibroblasts, but not in epidermal
keratinocytes (Igarashi et al, 1993; Frazier et al, 1996;
Grotendorst et al, 1996). In contrast to the situation in
normal fibroblasts, CTGF is constitutively overexpressed in
dermal fibrotic lesions, such as in scleroderma (Igarashi
et al, 1996; Abraham et al, 2000; Shi-wen et al, 2000;
Holmes et al, 2001). These observations suggest that CTGF
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may act as a downstream effector of at least some of the
pro-fibrotic effects of TGF-b and therefore that blockading
CTGF might be expected to alleviate the symptoms of
fibrosis, but TGF-b-dependent, CTGF-independent events
unaltered (Grotendorst, 1997). This review focuses on the
role that connective tissue growth factor (CTGF, CCN2) may
play as marker and a mediator of the fibrotic phenotype of
the disease scleroderma.
CTGF functions
CTGF, a member of the CCN family of matricellular proteins
(Bork, 1993; Lau and Lam, 1999; Moussad and Brigstock,
2000; Perbal, 2001), promotes fibroblast proliferation,
matrix production, and granulation tissue formation (Brad-
ham et al, 1991; Frazier et al, 1996; Brigstock et al, 1997). In
addition, CTGF promotes cell adhesion and migration in a
wide variety of cell types (Kireeva et al, 1997; Babic et al,
1999; Shimo et al, 1999; Crean et al, 2002). During
development, CTGF is strongly expressed in mesenchyme
such as in hypertrophic chondrocytes in the growth plate of
cartilage, the developing glomerulus and connective tissue
surrounding developing muscle (Yamamoto et al, 2002;
Friedrichsen et al, 2003). In addition, CTGF is expressed in
the placenta during embryo implantation (Surveyor et al,
1998) and during ovarian follicogenesis (Slee et al, 2001).
Recently, CTGF knockout mice were generated. The
phenotype of these mice is consistent with a role for CTGF
in matrix synthesis and remodeling and cell proliferation and
migration. Mice homozygous for a deletion of the CTGF
gene die soon after birth, displaying an inability of the rib
cage to ossify properly, including a failure of the embryo to
induce expression of bone-specific matrix, such as aggre-
can, and a failure of chondrocyte proliferation (Ivkovic et al,
2003). CTGF knockout mice also display a reduction in the
number of capillaries invading cartilage (Ivkovic et al, 2003).
CTGF knockout animals also show a decreased expression
of the pro-angiogenic factor vascular endothelial growth
factor (Ivkovic et al, 2003). These activities are consistent
with the notion that recombinant CTGF induces chondro-
cyte differentiation and proliferation in vitro (Nakanishi et al,
2000) through p38 and mitogen-activated protein kinase,
respectively (Yosimichi et al, 2001), and angiogenesis in vivo
and in vitro (Babic et al, 1999; Shimo et al, 1999, 2001).
CTGF receptors
In spite of substantial efforts expended by several labora-
tories, a specific CTGF receptor has not yet been identified.
Rather, CTGF promotes many of its activities by binding to
integrins (Lau and Lam, 1999). For example, CTGF
promotes angiogenesis endothelial cells through integrin
avb3 (Babic et al, 1999), and adhesion to human foreskin
fibroblasts through integrin a6b1, to human platelets
through integrin aIIb3, to endothelial cells through avb3
and to blood monocytes through integrin aMb2 (Babic et al,
1999; Jedsadayanmata et al, 1999; Chen CC et al, 2001;
Schober et al, 2002). CTGF directly binds integrin a6b1
through a motif in the carboxyl-terminal half of CTGF (Leu
et al, 2003), in the so-called thrombospondin motif (for
review, see Perbal, 2001). Functional studies, however, have
emphasized the essential nature of the heparin-binding
domain of CTGF, which is carboxy-terminal of the throm-
bospondin motif, in CTGF-mediated fibroblast proliferation
and attachment (Brigstock et al, 1997; Ball et al, 2003a).
These results suggest that the ability of CTGF to bind cell
surface heparin sulfate proteoglycans is essential for CTGF
activity. Indeed, CTGF-mediated adhesive signaling pos-
sesses both integrin- and heparin sulfate proteoglycan-
mediated components (Chen CC et al, 2001). Although the
specific heparin sulfate proteoglycans and heparin side
chains that bind CTGF have not been fully elucidated, a
recent report found that the ability of CTGF to induce
chondrocyte proliferation and migration required the hepar-
in sulfate proteoglycan perlecan (Nishida et al, 2003). Thus,
the available evidence suggests that CTGF mediate its
effects through integrin- and heparin sulfate proteoglycan-
dependent mechanisms. Iodinated CTGF has also been
shown to interact with the low-density lipoprotein receptor
(Segarini et al, 2001). This interaction has not yet been
shown to result in a CTGF-mediated signaling event, but is
involved with CTGF internalization and degradation in the
endosome (Chen Y et al, 2001; Segarini et al, 2001).
CTGF and TGF-b synergize to promote a
sustained ﬁbrotic response
CTGF has been directly implicated in the excessive matrix
deposition characteristic of scleroderma lesions. Experi-
ments using recombinant CTGF and neutralizing antibodies
targeting CTGF have suggested that CTGF mediates at
least some of the effects of TGF-b on fibroblast prolifera-
tion, adhesion, and ECM production (Grotendorst, 1997;
Duncan et al, 1999; Lau and Lam, 1999). One of the most
compelling pieces of evidence showing CTGF can inde-
pendently induce matrix is that an expression vector
encoding CTGF transfected into fibroblasts can activate a
cotransfected reporter construct driven by the type I
collagen promoter (Shi-wen et al, 2000). These results
suggest that a CTGF response element exists in the type I
collagen promoter. Studies are currently underway to
identify the cis-acting sequences, trans-acting factors
and signal transduction mechanisms involved with this
response.
Physiologically, the effect of CTGF induced by TGF-b
might result in a prolonged induction of expression of
collagen mRNA. In fact, CTGF seems act with TGF-b to
promote a sustained fibrotic response. Mori et al (1999)
showed that subcutaneous injection of TGF-b into neonatal
mice caused a transient fibrotic response, which dissipated
when ligand was no longer injected. Conversely, although
injection of CTGF alone had little effect, coinjection of CTGF
and TGF-b resulted in sustained fibrosis that persisted for at
least a week after cessation of injection (Mori et al, 1999).
Other experiments have shown that CTGF alone causes an
increase in matrix deposition when injected subcutaneously
(Frazier et al, 1996; Ball et al, 2003b). Recently it was
shown, using an adenoviral delivery system, that over-
expression of CTGF in lung tissue caused a modest,
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transient fibrosis, suggesting that another stimulus might be
required for sustained fibrosis (Bonniaud et al, 2003).
Alternatively, it was recently suggested that CTGF may
bind to TGF-b and potentiate TGF-b binding to the TGF-b
type II receptors and thus contribute to the effects of TGF-b
on cells, for example, by promoting activation of Smad, at
least in Xenopus (Abreu et al, 2002). The relevance of these
latter observations to mammalian systems is currently
under investigation. The available data, however, suggest
that, whereas TGF-b or CTGF alone may only result in
transient fibrosis, TGF-b in the presence of high levels of
CTGF may result in a sustained fibrotic response.
Elevated levels CTGF expression in
scleroderma ﬁbroblasts are independent of
the TGF-b response element of the CTGF
promoter but dependent on Sp1
It has long been known that TGF-b induction of collagen
occurs directly in an immediate early fashion, requiring
action of the general TGF-b signaling mediators the Smad
(Chen et al, 1999). The Smad family of proteins has been
extensively reviewed (for example, Roberts, 1999; Attisano
and Wrana, 2002; Verrecchia and Mauviel, 2002). Briefly, in
the presence of TGF-b ligand, the receptor-activated Smad,
Smad2 and 3, are phosphorylated directly by the TGF-b
receptor I kinase and then translocate to the nucleus
complexed to the common mediator, Smad4. Maximal
affinity of recombinant Smad3 and Smad4 to DNA is
observed with the 5 bp sequence, CAGAC (Zawel et al,
1998). Smad2, on the other hand, does not bind DNA
directly, requiring a nuclear DNA-binding protein of the Fast
family to bind DNA, in association with Smad4, and activate
transcription in response to TGF-b and activin (Liu et al,
1999). A third group of Smad proteins, the inhibitory Smad
(I-Smad), such as Smad6 or Smad7 prevent R-Smad
phosphorylation and subsequent nuclear translocation of
R-Smad/Smad4 heterocomplexes (Nakao et al, 1997).
Smad 3 is essential for the induction of matrix (Verrecchia
et al, 2001b). Indeed, a functional Smad element resides
within the CTGF promoter; the TGF-b induction of CTGF is
grossly impaired in embryonic fibroblasts taken from
Smad3 knockout mice (Holmes et al, 2001; Fig 1). In
addition to the Smad binding element, the TGF-b-induction
of CTGF also requires a consensus TEF binding element
(Leask et al, 2003; Fig 1).
Smad3 is essential for the initiation of fibrosis; radiation-
induced fibrosis does not develop in Smad3 knockout
animals (Flanders et al, 2002). Consistent with this idea,
elevated levels of Smad3 and phosphorylated Smad3 are
observed during bleomycin-induced skin fibrosis for 3 wk
after injection of bleomycin (Takagawa et al, 2003). Another
study from the same group examined the level of unpho-
sphorylated and phosphorylated Smad3 present in SSc
fibroblasts cultured from the leading edge of the fibrotic
lesion (Mori et al, 2003); that is, in the area of the fibrotic
lesion involved with the initiation and expansion of the
fibrotic response. In this latter study, elevated levels of
phosphorylated Smad3 and expression of a generic
Smad3-responsive promoter were observed in leading
edge SSc fibroblasts relative to normal fibroblasts (Mori
et al, 2003). Collectively, these results suggest that an
elevated level of Smad3 activation is involved with the
initiation of the fibrotic response in SSc. When we examined
Smad expression in SSc fibroblasts cultured from estab-
lished fibrotic lesions, however, we were not able to show a
consistent pattern of Smad3 overexpression (Holmes et al,
2001). Thus, it is not clear whether a generally activated
Smad3-dependent signaling pathway is sufficient to result
in prolonged pathologic fibrosis. For example, it remains to
be seen if every transcript that is Smad3 responsive is
overexpressed in lesional SSc fibroblasts, or if every gene
overexpressed in lesional SSc fibroblasts is Smad3 respon-
sive in normal fibroblasts. In addition, it remains to be seen
if activity of a generic Smad3-responsive promoter is
upregulated in SSc fibroblasts cultured from established
lesions.
In contrast to the situation in normal dermal fibroblasts,
CTGF is constitutively overexpressed in dermal fibrotic
lesions, such as in scleroderma (Igarashi et al, 1996;
Abraham et al, 2000; Shi-wen et al, 2000; Holmes et al,
2001). As CTGF is thus an effective marker of an activated,
sclerotic fibroblast, examining the mechanism underlying
the overexpression of CTGF in fibroblasts cultured from
fibrotic lesions is likely to provide insights into under-
standing the mechanism underlying persistent fibrosis.
Thus to probe the molecular mechanism underlying the
maintenance of the fibrotic phenotype and to investigate the
role of Smad-dependent and Smad-independent signaling
pathways in the maintenance of the fibrotic phenotype in
established SSc lesions, we have identified elements in the
CTGF promoter required for its overexpression in lesional
SSc fibroblasts. We found that the elevated expression of
the CTGF promoter in SSc fibroblasts seems to be
independent of its Smad response element (Holmes et al,
2001) and TGF-b response element (Leask et al, 2003).
Instead, the elevated expression of the CTGF promoter in
SSc fibroblasts was dependent, at least in part, on an Sp1
Figure1
The regulation of CTGF in normal and scleroderma fibroblasts. A
diagram of the CTGF promoter is shown, with the elements that are
required for the expression of CTGF in normal and scleroderma
fibroblasts. The expression of CTGF in normal fibroblasts requires
induction by TGF-b and its TGF-b response element, namely Smad and
TEF recognition sequences (circles with stippled and vertical lines,
respectively; Holmes et al, 2001; Leask et al, 2003). The expression of
CTGF in scleroderma fibroblasts requires an Sp1-binding element
(open box; Holmes et al, 2003) and is independent of the TGF-b
response element of the CTGF promoter.
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binding element in the CTGF promoter and an elevated level
of Sp1 DNA binding present in nuclear extracts prepared
from scleroderma fibroblasts (Holmes et al, 2003; Fig 1). The
Sp1 element of the CTGF promoter was not required for the
ability of the CTGF promoter to respond to TGF-b (Holmes
et al, 2003). Previously, it was shown that Sp1 regulates a
wide variety of matrix genes (Verrecchia et al, 2001c).
Intriguingly, the transcription factor fli-1, which suppresses
collagen promoter activity through an Sp1-dependent
mechanism (Czuwara-Ladykowska et al, 2001), was re-
cently found to be markedly downregulated in SSc lesions
(Kubo et al, 2003). Collectively, these results suggest that
elevation of matrix genes in lesional SSc fibroblasts may
involve elevated Sp1 activity.
The divergence between the requirement of TGF-b for
the induction of CTGF in normal fibroblasts and the
constitutive, elevated level of CTGF expression in scler-
oderma dermal fibroblasts is supported by other observa-
tions. Histologic studies examining the distribution of CTGF
and TGF-b mRNA in skin sections showed that in diffuse
SSc lesions TGF-b expression is only overexpressed in the
leading inflammatory edge of the lesion, but not in the
lesional area itself (Querfeld et al, 1999). In contrast, CTGF
shows an expression pattern that correlates with the
severity of fibrosis; that is, CTGF expression is abundant
in fibrotic lesions, even in the absence of markedly elevated
amounts of TGF-b ligand (Sato et al, 2000). Additional data
suggesting that the elevated level of CTGF expression in
fibrotic lesions is TGF-b-independent comes from data
showing that tumor necrosis factor a, which is believed to
contribute to the downregulation of the fibrotic response
in vivo in part through the suppression Smad activity in
fibroblasts (Verrecchia et al, 2000), blocks the ability of TGF-
b to induce CTGF in normal and SSc fibroblasts, but
does not affect the basal, constitutive levels of expression
of CTGF observed in scleroderma fibroblasts (Abraham
et al, 2000). Taken together, in contrast to the situation in
normal dermal fibroblasts whereby CTGF is not normally
expressed unless induced by TGF-b through the TGF-b
response element, the persistent level of CTGF observed in
lesional SSc fibroblasts seems to be independent of TGF-b
ligand.
Hypothesis: The elevated, TGF-b-
independent levels of CTGF promotes a
sustained ﬁbrotic response in scleroderma
TGF-b and the TGF-b signaling mediators, the Smad, are
necessary for the induction of fibrosis in animal models
(McCormick et al, 1999; Nakao et al, 1999; Yamamoto et al,
1999; Terada et al, 2002; Lan et al, 2003). In animal models,
however, whereas subcutaneous injection of TGF-b or
CTGF alone only causes a transient fibrotic response,
simultaneous injection of TGF-b and CTGF—that is, when
CTGF is present in levels over and above those normally
induced by TGF-b—causes a sustained fibrotic response
(Mori et al, 1999). We hypothesize that in the normal wound
healing response, the upregulation of CTGF is dependent
on the TGF-b response element of the CTGF promoter, and
is therefore subject to the controls that normally negatively
regulate the TGF-b-induced wound healing response, such
as tumor necrosis factor a (Abraham et al, 2000; Fig 2). In
pathologic fibrosis, however, fibroblasts display an elevated
level of CTGF expression that is independent of the TGF-b
response element of the CTGF promoter (Holmes et al,
2001, 2003). Thus, the elevated level of CTGF expression
observed in the scleroderma fibroblast is therefore not
subject to the negative regulatory controls that normally
suppress the TGF-b-induced wound healing response. In
fact, it is tempting to speculate that, whereas TGF-b is
essential for the initiation of fibrosis it is the persistent, TGF-
b-independent CTGF expression characteristic of fibrotic
lesions perpetuates the wound healing response, resulting
in sustained, chronic, pathologic fibrosis (Fig 2).
In conclusion, the observations concerning CTGF ex-
pression and function have led to the intriguing notion that
CTGF might be a novel, molecular target for therapeutic
Figure 2
Model of sustained, chronic fibrosis. TGF-b is
necessary for the initiation of the normal wound healing
response, including the expression of ECM and CTGF in
dermal fibroblasts. In the normal wound healing
response, the action of TGF-b, including the induction
of CTGF, is suppressed leading to the proper termina-
tion of the wound healing response (black arrow).
Conversely in pathologic fibrosis, the expression of
CTGF in the lesion is independent of TGF-b action. Thus
CTGF expression is not subject to controls that
normally terminate the wound healing response. The
fibrotic response persists, leading to sustained, chronic
fibrosis (gray arrow). The phases of the normal wound
healing and fibrotic response are shown, and the
effectors of the fibrotic response are shown at the top
of the diagram.
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intervention in fibrotic disease (Grotendorst, 1997; Perbal,
2001; Leask et al, 2002; Rachfal and Brigstock, 2003). As
further research is conducted, the precise functional role of
CTGF concerning the regulation of cellular function should
emerge, and result in the development of novel methods for
anti-fibrotic intervention to prevent dermal scarring and
alleviate the symptoms of fibrosis.
DOI: 10.1046/j.0022-202X.2003.22133.x
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